ENANTIOSELECTIVE DISPOSITION OF ORAL AMLODIPINE IN HEALTHY-VOLUNTEERS

被引:16
作者
LAUFEN, H
LEITOLD, M
机构
[1] Pfizer Mack Research and Development Laboratories, Illertissen
关键词
(R)-AMLODIPINE; (S)-AMLODIPINE; (R; S)-AMLODIPINE; PHARMACOKINETICS; ORAL DOSAGE; HUMAN STUDY;
D O I
10.1002/chir.530060704
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Plasma concentrations of (R)- and (S)-amlodipine were measured after single oral administrations to 18 healthy volunteers of 20 mg amlodipine racemate. The contribution of the pharmacologically active (S)-enantiomer to the concentrations of total amlodipine (sum of enantiomers) was significantly higher than that of the inactive (R)-enantiomer, with mean values of 47% R to 53% S for the C-max and 41% R to 59% S for the AUC (range between 24% R:76% S and 50% R:50% S). The oral clearance of the active (S)-form was subject to much less intersubject variation (25% CV) than that of the inactive (R)-form (52% CV). (R)-Amlodipine was more rapidly eliminated from plasma than (S)-amlodipine, with mean terminal half-lives of 34.9 h (R) and 49.6 h (S). The terminal half-lives of total amlodipine (mean 44.2 h) were strongly correlated with-and thus highly predictive for-the half-lives of the (S)-enantiomer. It is proposed that the observed enantioselectivity of oral amlodipine is due to differences in the systemic blood clearance of the enantiomers. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码:531 / 536
页数:6
相关论文
共 10 条
[1]   LONG-ACTING DIHYDROPYRIDINE CALCIUM-ANTAGONISTS .1. 2-ALKOXYMETHYL DERIVATIVES INCORPORATING BASIC SUBSTITUENTS [J].
ARROWSMITH, JE ;
CAMPBELL, SF ;
CROSS, PE ;
STUBBS, JK ;
BURGES, RA ;
GARDINER, DG ;
BLACKBURN, KJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (09) :1696-1702
[2]  
FAULKNER JD, 1986, BR J CLIN PHARM, V27, P21
[3]   DETERMINATION OF THE ABSOLUTE-CONFIGURATION OF THE ACTIVE AMLODIPINE ENANTIOMER AS (-)-S - A CORRECTION [J].
GOLDMANN, S ;
STOLTEFUSS, J ;
BORN, L .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (18) :3341-3344
[4]   AN ALGORITHM FOR LEAST-SQUARES ESTIMATION OF NONLINEAR PARAMETERS [J].
MARQUARDT, DW .
JOURNAL OF THE SOCIETY FOR INDUSTRIAL AND APPLIED MATHEMATICS, 1963, 11 (02) :431-441
[5]   CLINICAL PHARMACOKINETICS OF AMLODIPINE [J].
MEREDITH, PA ;
ELLIOTT, HL .
CLINICAL PHARMACOKINETICS, 1992, 22 (01) :22-31
[6]   AMLODIPINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN CARDIOVASCULAR-DISEASE [J].
MURDOCH, D ;
HEEL, RC .
DRUGS, 1991, 41 (03) :478-505
[7]  
SCHARPF F, 1994, J CHROMATOGR, V655, P226
[8]   THE METABOLISM AND PHARMACOKINETICS OF AMLODIPINE IN HUMANS AND ANIMALS [J].
STOPHER, DA ;
BERESFORD, AP ;
MACRAE, PV ;
HUMPHREY, MJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 12 :S55-S59
[9]   SYMMETRICAL CONFIDENCE-INTERVALS FOR BIOEQUIVALENCE TRIALS [J].
WESTLAKE, WJ .
BIOMETRICS, 1976, 32 (04) :741-744
[10]  
WILKINSON GR, 1975, CLIN PHARMACOL THER, V18, P377